These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23929508)

  • 1. Predicting the posttransplant prognosis of patients with hepatocellular carcinoma: what lies beneath alpha-fetoprotein?
    Giannini EG; Savarino V
    Liver Transpl; 2013 Oct; 19(10):1166-7. PubMed ID: 23929508
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
    Berry K; Ioannou GN
    Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Fetoprotein and hepatocellular cancer recurrence: a paradigm of the chaos theory.
    Lai Q; Lerut J;
    Liver Transpl; 2014 Oct; 20(10):1283. PubMed ID: 25060782
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there an ideal cutoff for α-fetoprotein as an exclusion criterion for liver transplantation?
    de Mattos AA; dos Santos Schraiber L; Zanotell ML; Cantisani G
    Liver Transpl; 2014 Oct; 20(10):1284. PubMed ID: 25044482
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis--conclusion about locoregional therapy.
    Tchilikidi KY
    Clin Transplant; 2013; 27(4):483. PubMed ID: 23923968
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to letter to the editors.
    Yao FY; Hameed B; Mehta N; Roberts JP
    Liver Transpl; 2014 Oct; 20(10):1285. PubMed ID: 25155484
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic Recurrent Hepatocellular Carcinoma Post Liver Transplant With Marked Pretransplant Elevation of Alpha Fetoprotein and No Evidence of Primary Neoplasm.
    Kumar S
    Exp Clin Transplant; 2018 Feb; 16(1):99-102. PubMed ID: 26789285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent.
    Chen LT; Shiah HS; Chao Y; Chang JY; Cheng LT; Whang-Peng J
    J Clin Oncol; 2009 Dec; 27(36):e271; author reply e272. PubMed ID: 19917866
    [No Abstract]   [Full Text] [Related]  

  • 9. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma.
    Kilickap S; Arslan C; Senel S; Ataseven H
    J Clin Oncol; 2010 Feb; 28(6):e99; author reply e100. PubMed ID: 20085931
    [No Abstract]   [Full Text] [Related]  

  • 10. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
    Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
    Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma.
    Meng W; Bai B; Bai Z; Li Y; Yue P; Li X; Qiao L
    Discov Med; 2016 Jun; 21(118):489-94. PubMed ID: 27448785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-fetoprotein in early hepatocellular carcinoma.
    Marrero JA; Feng Z
    Gastroenterology; 2010 Jan; 138(1):400-1. PubMed ID: 19932214
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.
    Mailey B; Artinyan A; Khalili J; Denitz J; Sanchez-Luege N; Sun CL; Bhatia S; Nissen N; Colquhoun SD; Kim J
    Arch Surg; 2011 Jan; 146(1):26-33. PubMed ID: 21242442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.
    Mehta N; Yao FY
    Liver Transpl; 2013 Oct; 19(10):1055-8. PubMed ID: 23959652
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
    Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivals after liver transplantation for hepatocellular carcinoma: Granular data for a better allocation process?
    Lai Q; Rossi M
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):374-375. PubMed ID: 29866607
    [No Abstract]   [Full Text] [Related]  

  • 17. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead.
    Giannini EG; Farinati F; Trevisani F
    Hepatology; 2011 Jul; 54(1):376-7. PubMed ID: 21710475
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatocellular carcinoma - diagnosis and treatment].
    Greten TF; Manns MP
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1907-10. PubMed ID: 18785082
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic markers as predictors for liver transplant outcome.
    Freeman RB
    Am J Transplant; 2010 Jan; 10(1):10-1. PubMed ID: 19951278
    [No Abstract]   [Full Text] [Related]  

  • 20. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
    J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.